OBJECTIVE: To probe into the pharmaceutical intervention on patients with peptic ulcer and Helicobacter pylori（ H. pylori） infection by clinical pharmacists. METHODS: A total of 86 patients with peptic ulcer and H. pylori infection met the inclusion and exclusion criteria from Kashgar District Second People’s Hospital from Jul.2018 to Jun. 2020 were extracted to be divided into the intervention group and the control group via the random number table

with 43 cases in each group. Both groups were treated with quadruple therapy for 10 d. Treatment with proton pump inhibitors and bismuth was continued after the end of eradication therapy

with 6 to 8 weeks for gastric ulcers and4 to 6 weeks for duodenal bulb ulcers. The control group received the routine diagnosis and treatment procedure

while the intervention group was treated with the pharmaceutical intervention through the pharmaceutic ward round model in hospital

the intervention group were provided with diary card after discharge and were routinely telephone followed-up by pharmacists at home besides the routine procedure. Both groups were surveyed before discharge and were assessed the medication compliance and the incidence of adverse drug reactions when the treatment was finished

the eradication rate of H. pylori was evaluated by14 C urea breath test after drug withdrawal of 30 d. Telephone follow-up was performed at the end of treatment

30 d after treatment and 6 months after treatment for remission of peptic ulcer disease symptoms. RESULTS: The success rate of pharmaceutical interventions by clinical pharmacists for patients in the intervention group during the hospitalization was 100%. At the time of discharge

the questionnaire evaluation of patients in the intervention group was significantly better than the control group in proportion of patients with correct medication

proportion of patients with knowledge of course of treatment

score of understanding of adverse reactions and satisfaction

with statistical significant differences（ P < 0. 05）. The eradication rates of H. pylori in the intervention group and the control group were respectively 81. 40%（ 35/43） and 74. 42%（ 32/43）

the difference was not statistically significant（ P > 0. 05）. There was no significant difference in gastrointestinal symptom rating scale scores between two groups in telephone follow-up at the end of treatment

30 d after treatment and 6 months after treatment（ P > 0. 05）. The proportion of patients without missed medication in the intervention group and control group were respectively 90. 70%（ 39/43） and 41. 86%（ 18/43）

the difference was statistically significant（ P < 0. 001）.The incidence of adverse drug reactions in the intervention group was 37. 21%（ 16/43）

significantly lower than that in the control group 62. 79%（ 27/43）

the difference was statistically significant（ P < 0. 05）. CONCLUSIONS:Pharmaceutical intervention by clinical pharmacists can improve the medication accuracy

compliance and satisfaction of pharmaceutical care in patients with peptic ulcer and H. pylori infection.